A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug Carmela FimognariLuca SangiorgiPatrizia Hrelia OriginalPaper Pages: 195 - 203
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines Frank MayerSandra MuellerCarsten Bokemeyer OriginalPaper Pages: 205 - 211
Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumors Jian LiangRichard E. MooreThomas H. Corbett OriginalPaper Pages: 213 - 224
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam Charlotte van KesterenAnthe S. ZandvlietJan H. M. Schellens OriginalPaper Pages: 225 - 234
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy Dean LimRobert J. Morgan Jr.James H. Doroshow OriginalPaper Pages: 235 - 239
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer Heather WakeleeGeorge A. Fisher OriginalPaper Pages: 241 - 242
Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer M. MéndezP. G. AlfonsoJ. J. Cruz OriginalPaper Pages: 243 - 251
Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma Michael J. MillwardAnthony JoshuaKevin Lynch OriginalPaper Pages: 253 - 256
Phase II trial of dolastatin-10 in patients with advanced breast cancer Edith A. PerezDavid W. HillmanShaker R. Dakhil OriginalPaper Pages: 257 - 261
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer Johan VansteenkisteJean-Luc CanonMichael Lahn OriginalPaper Pages: 263 - 269